Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease

Neurobiology of Disease

Volumn 10, Issue 3, 2002, Pages 410-426

  Blum, David ^a   Galas, Marie Christine ^a   Gall, David ^a   Cuvelier, Laetitia ^a   Schiffmann, Serge N ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

3 nitropropionic acid; Cell death; Huntington's disease; Lewis rat; mRNA; Receptor

Indexed keywords

3 NITROPROPIONIC ACID; ADENOSINE A2A RECEPTOR; CYTOCHROME C OXIDASE; DOPAMINE 1 RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SUCCINATE DEHYDROGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BRAIN CORTEX; BRAIN DEGENERATION; BRAIN NERVE CELL; BRAIN REGION; CELL FATE; CONTROLLED STUDY; CORPUS STRIATUM; HUNTINGTON CHOREA; MALE; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; RECEPTOR UPREGULATION;

EID: 0036405496     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1006/nbdi.2002.0512     Document Type: Article

References (78)

1. Antonini, A., Leenders, K. L., Spiegel, R., Meier, D., Vontobel, P., Weigell-Weber, M., Sanchez-Pernaute, R., de Yebenez, J. G., Boesiger, P., Weindl, A., & Maguire, R. P. (1996) Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 119 (Pt 6), 2085-2095
2. Araujo, D. M., Cherry, S. R., Tatsukawa, K. J., Toyokuni, T., & Kornblum, H. I. (2000) Deficits in striatal dopamine D(2) receptors and energy metabolism detected by in vivo microPET imaging in a rat model of Huntington's disease. Exp. Neurol. 166, 287-297.
3. Arenas, E., Akerud, P., Wong, V., Boylan, C., Persson, H., Lindsay, R. M., & Altar, C. A. (1996) Effects of BDNF and NT-4/5 on striatonigral neuropeptides or nigral GABA neurons in vivo. Eur. J. Neurosci. 8, 1707-1717.
4. Augood, S. J., Faull, R. L., & Emson, P. C. (1997) Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann. Neurol. 42, 215-221.
5. Beal, M. F., & Hantraye, P. (2001) Novel therapies in the search for a cure for Huntington's disease. Proc. Natl. Acad. Sci. USA 98, 3-4.
6. Beal, M. F. (2000) Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci. 23, 298-304.
7. Beal, M. F., Brouillet, E., Jenkins, B. G., Ferrante, R. J., Kowall, N. W., Miller, J. M., Storey, E., Srivastava, R., Rosen, B. R., & Hyman, B. T. (1993) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13, 4181-4192.
8. Benfenati, F., Pich, E. M., Grimaldi, R., Zoli, M., Fuxe, K., Toffano, G., & Agnati, L. F. (1989) Transient forebrain ischemia produces multiple deficits in dopamine D1 transmission in the lateral neostriatum of the rat. Brain Res. 498, 376-380.
9. Benfenati, F., Cimino, M., Zoli, M., Grimaldi, R., Zini, I., & Agnati, L. F. (1991) Decrease in mRNA levels but not in the density of D2 dopamine receptors in rat striatum after transient forebrain ischemia. Neurosci. Lett. 126, 6-8.
10. Bibb, J. A., Yan, Z., Svenningsson, P., Snyder, G. L., Pieribone, V. A., Horiuchi, A., Nairn, A. C., Messer, A., & Greengard, P. (2000) Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc. Natl. Acad. Sci. USA 97, 6809-6814.
11. Blum, D., Gall, D., Cuvelier, L., & Schiffmann, S. N. (2001) Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat. Neuroreport 12, 1769-1772.
12. Brickell, K. L., Nicholson, L. F., Waldvogel, H. J., & Faull, R. L. (1999) Chemical and anatomical changes in the striatum and substantia nigra following quinolinic acid lesions in the striatum of the rat: A detailed time course of the cellular and GABA(A) receptor changes. J. Chem. Neuroanat. 17, 75-97.
13. Brouillet, E., Hantraye, P., Ferrante, R. J., Dolan, R., Leroy-Willig, A., Kowall, N. W., & Beal, M. F. (1995) Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. Natl. Acad. Sci. USA 92, 7105-7109.
14. Brouillet, E., Guyot, M. C., Mittoux, V., Altairac, S., Conde, F., Palfi, S., & Hantraye, P. (1998) Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. J. Neurochem. 70, 794-805.
15. Brouillet, E., Conde, F., Beal, M. F., & Hantraye, P. (1999) Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol. 59, 427-468.
16. Canals, J. M., Checa, N., Marco, S., Akerud, P., Michels, A., Perez-Navarro, E., Tolosa, E., Arenas, E., & Alberch, J. (2001) Expression of brain-derived neurotrophic factor in cortical neurons is regulated by striatal target area. J. Neurosci. 21, 117-124.
17. Cha, J. H., Kosinski, C. M., Kerner, J. A., Alsdorf, S. A., Mangiarini, L., Davies, S. W., Penney, J. B., Bates, G. P., & Young, A. B. (1998) Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc. Natl. Acad. Sci. USA 95, 6480-6485.
18. Cha, J. H., Frey, A. S., Alsdorf, S. A., Kerner, J. A., Kosinski, C. M., Mangiarini, L., Penney, J. B., Jr., Davies, S. W., Bates, G. P., & Young, A. B. (1999) Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos. Trans. R. Soc. Lond B Biol. Sci. 354, 981-989.
19. Cha, J. H. (2000) Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 23, 387-392.
20. Changelian, P. S., Feng, P., King, T. C., & Milbrandt, J. (1989) Structure of the NGFI-A gene and detection of upstream sequences responsible for its transcriptional induction by nerve growth factor. Proc. Natl. Acad. Sci. USA 86, 377-381.
21. Chen, N., Luo, T., Wellington, C., Metzler, M., McCutcheon, K., Hayden, M. R., & Raymond, L. A. (1999) Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. J. Neurochem. 72, 1890-1898.
22. Dassesse, D., Vanderwinden, J. M., Goldberg, I., Vanderhaeghen, J. J., & Schiffmann, S. N. (1999) Caffeine-mediated induction of c-fos, zif-268 and arc expression through A1 receptors in the striatum: Different interactions with the dopaminergic system. Eur. J. Neurosci. 11, 3101-3114.
23. Dassesse, D., Massie, A., Ferrari, R., Ledent, C., Parmentier, M., Arckens, L., Zoli, M., & Schiffmann, S. N. (2001) Functional striatal hypodopaminergic activity in mice lacking adenosine A(2A) receptors. J. Neurochem. 78, 183-198.
24. Dautry, C., Conde, F., Brouillet, E., Mittoux, V., Beal, M. F., Bloch, G., & Hantraye, P. (1999) Serial 1H-NMR spectroscopy study of metabolic impairment in primates chronically treated with the succinate dehydrogenase inhibitor 3-nitropropionic acid. Neurobiol. Dis. 6, 259-268.
25. Dautry, C., Vaufrey, F., Brouillet, E., Bizat, N., Henry, P. G., Conde, F., Bloch, G., & Hantraye, P. (2000) Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3-nitropropionic acid. J. Cereb. Blood Flow Metab. 20, 789-799.
26. Denovan-Wright, E. M., & Robertson, H. A. (2000) Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. Neuroscience 98, 705-713.
27. DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., & Aronin, N. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990-1993.
28. El Massioui, N., Ouary, S., Cheruel, F., Hantraye, P., & Brouillet, E. (2001) Perseverative behavior underlying attentional set-shifting deficits in rats chronically treated with the neurotoxin 3-nitropropionic acid. Exp. Neurol. 172, 172-181.
29. Esclapez, M., Tillakaratne, N. J., Kaufman, D. L., Tobin, A. J., & Houser, C. R. (1994) Comparative localization of two forms of glutamic acid decarboxylase and their mRNAs in rat brain supports the concept of functional differences between the forms. J. Neurosci. 14, 1834-1855.
30. Ferreira, J. M., & Paes-de-Carvalho, R. (2001) Long-term activation of adenosine A(2a) receptors blocks glutamate excitotoxicity in cultures of avian retinal neurons. Brain Res. 900, 169-176.
31. Fink, J. S., Weaver, D. R., Rivkees, S. A., Peterfreund, R. A., Pollack, A. E., Adler, E. M., & Reppert, S. M., (1992) Molecular cloning of the rat A2 adenosine receptor: Selective coexpression with D2 dopamine receptors in rat striatum. Brain Res. Mol. Brain Res. 14, 186-195.
32. Galas, M. C., Chasserot-Golaz, S., Dirrig-Grosch, S., & Bader, M. F. (2000) Presence of dynamin-Syntaxin complexes associated with secretory granules in adrenal chromaffin cells. J. Neurochem. 75, 1511-1519.
33. Glass, M., Dragunow, M., & Faull, R. L. (2000) The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97, 505-519.
34. Guyot, M. C., Hantraye, P., Dolan, R., Palfi, S., Maziere, M., & Brouillet, E. (1997) Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. Neuroscience 79, 45-56.
35. Hodgson, J. G., Agopyan, N., Gutekunst, C. A., Leavitt, B. R., LePiane, F., Singaraja, R., Smith, D. J., Bissada, N., McCutcheon, K., Nasir, J., Jamot, L., Li, X. J., Stevens, M. E., Rosemond, E., Roder, J. C., Phillips, A. G., Rubin, E. M., Hersch, S. M., & Hayden, M. R. (1999) A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23, 181-192.
36. Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983.
37. Kim, H. S., Lee, S. J., Kim, D. S., & Cho, H. J. (2000) Effects of brain-derived neurotrophic factor and neurotrophin-3 on expression of mRNAs encoding c-Fos, neuropeptides, and glutamic acid decarboxylase in cultured spinal neurons. Neuroreport 11, 3873-3876.
38. Jenkins, B. G., Klivenyi, P., Kustermann, E., Andreassen, O. A., Ferrante, R. J., Rosen, B. R., & Beal, M. F. (2000) Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. J. Neurochem. 74, 2108-2119.
39. Kunig, G., Leenders, K. L., Sanchez-Pernaute, R., Antonini, A., Vontobel, P., Verhagen, A., & Gunther, I. (2000) Benzodiazepine receptor binding in Huntington's disease: [11C]Flumazenil uptake measured using positron emission tomography. Ann. Neurol. 47, 644-648.
40. Ledent, C., Vaugeois, J. M., Schiffmann, S. N., Pedrazzini, T., El Yacoubi, M., Vanderhaeghen, J. J., Costentin, J., Heath, J. K., Vassart, G., & Parmentier, M. (1997) Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 388, 674-678.
41. Lee, F. S., & Chao, M. V. (2001) Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proc. Natl. Acad. Sci. USA 98, 3555-3560.
42. Levine, M. S., Klapstein, G. J., Koppel, A., Gruen, E., Cepeda, C., Vargas, M. E., Jokel, E. S., Carpenter, E. M., Zanjani, H., Hurst, R. S., Efstratiadis, A., Zeitlin, S., & Chesselet, M. F. (1999) Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J. Neurosci. Res. 58, 515-532.
43. Luthi-Carter, R., Strand, A., Peters, N. L., Solano, S. M., Hollingsworth, Z. R., Menon, A. S., Frey, A. S., Spektor, B. S., Penney, E. B., Schilling, G., Ross, C. A., Borchelt, D. R., Tapscott, S. J., Young, A. B., Cha, J. H., & Olson, J. M. (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 9, 1259-1271.
44. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., & Bates, G. P. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506.
45. Menalled, L. B., & Chesselet, M. F. (2002) Mouse models of Huntington's disease. Trends Pharmacol. Sci. 23, 32-39.
46. Michelsen, B. K., Petersen, J. S., Boel, E., Moldrup, A., Dyrberg, T., & Madsen, O. D. (1991) Cloning, characterization, and autoimmune recognition of rat islet glutamic acid decarboxylase in insulin-dependent diabetes mellitus. Proc. Natl. Acad. Sci. USA 88, 8754-8758.
47. Mizuno, K., Carnahan, J., & Nawa, H. (1994) Brain-derived neurotrophic factor promotes differentiation of striatal GABAergic neurons. Dev. Biol. 165, 243-256.
48. Monsma, F. J., Jr., McVittie, L. D., Gerfen, C. R., Mahan, L. C., & Sibley, D. R. (1989) Multiple D2 dopamine receptors produced by alternative RNA splicing. Nature 342, 926-929.
49. Monsma, F. J., Jr., Mahan, L. C., McVittie, L. D., Gerfen, C. R., & Sibley, D. R. (1990) Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation. Proc. Natl. Acad. Sci. USA 87, 6723-6727.
50. Monyer, H., Sprengel, R., Schoepfer, R., Herb, A., Higuchi, M., Lomeli, H., Burnashev, N., Sakmann, B., & Seeburg, P. H. (1992) Heteromeric NMDA receptors: Molecular and functional distinction of subtypes. Science 256, 1217-1221.
51. Moriyoshi, K., Masu, M., Ishii, T., Shigemoto, R., Mizuno, N., & Nakanishi, S. (1991) Molecular cloning and characterization of the rat NMDA receptor. Nature 354, 31-37.
52. Nucifora, F. C., Jr., Sasaki, M., Peters, M. F., Huang, H., Cooper, J. K., Yamada, M., Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V. L., Dawson, T. M., & Ross, C. A. (2001) Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291, 2423-2428.
53. Ouary, S., Bizat, N., Altairac, S., Menetrat, H., Mittoux, V., Conde, F., Hantraye, P., & Brouillet, E. (2000) Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: Implications for neurprotection studies. Neuroscience 97, 521-530.
54. Page, K. J., Dunnett, S. B., & Everitt, B. J. (1998) 3-Nitropropionic acid-induced changes in the expression of metabolic and astrocyte mRNAs. Neuroreport 9, 2881-2886.
55. Page, K. J., Besret, L., Jain, M., Monaghan, E. M., Dunnett, S. B., & Everitt, B. J. (2000) Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and mu-opioid receptor binding in the basal ganglia. Exp. Brain Res. 130, 142-150.
56. Paxinos, G., & Watson, C. (1990) The Rat Brain in Stereotaxic Coordinates. Academic Press, New York.
57. Pranzatelli, M. R., Albin, R. L., & Cohen, B. H. (1991) Acute dyskinesias in young asthmatics treated with theophylline. Pediatr. Neurol. 7, 216-219.
58. Reiner, A., Albin, R. L., Anderson, K. D., D'Amato, C. J., Penney, J. B., & Young, A. B. (1988) Differential loss of striatal projection neurons in Huntington disease. Proc. Natl. Acad. Sci. USA 85, 5733-5737.
59. Richfield, E. K., Maguire-Zeiss, K. A., Vonkeman, H. E., & Voorn, P. (1995) Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients. Ann. Neurol. 38, 852-861.
60. Richter, A., Hamann, M., & Bartling, C. (2000) CGS 21680 exerts marked antidystonic effects in a genetic model of paroxysmal dyskinesia. Eur. J. Pharmacol. 404, 299-302.
61. Rutherford, L. C., DeWan, A., Lauer, H. M., & Turrigiano, G. G. (1997) Brain-derived neurotrophic factor mediates the activity-dependent regulation of inhibition in neocortical cultures. J. Neurosci. 17, 4527-4535.
62. Sapp, E., Ge, P., Aizawa, H., Bird, E., Penney, J., Young, A. B., Vonsattel, J. P., & DiFiglia, M. (1995) Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis. Neuroscience 64, 397-404.
63. Schiffmann, S. N., & Vanderhaeghen, J. J. (1993) Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J. Neurosci. 13, 1080-1087.
64. Schmued, L. C., Albertson, C., & Slikker, W., Jr. (1997) Fluoro-Jade: A novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res. 751, 37-46.
65. Sieradzan, K. A., & Mann, D. M. (2001) The selective vulnerability of nerve cells in Huntington's disease. Neuropathol. Appl. Neurobiol. 27, 1-21.
66. Simpson, J. R., & Isacson, O. (1993) Mitochondrial impairment reduces the threshold for in vivo NMDA-mediated neuronal death in the striatum. Exp. Neurol. 121, 57-64.
67. Sipione, S., & Cattaneo, E. (2001) Modeling huntington's disease in cells, flies, and mice. Mol. Neurobiol. 23, 21-51.
68. Steffan, J. S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y. Z., Gohler, H., Wanker, E. E., Bates, G. P., Housman, D. E., & Thompson, L. M. (2000) The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA 97, 6763-6768.
69. Stuart, A. M., Worley, L. M., & Spillane, J. (1992) Choreiform movements observed in an 8-year-old child following use of an oral theophylline preparation. Clin. Pediatr. (Philadelphia) 31, 692-694.
70. Sun, Y., Savanenin, A., Reddy, P. H., & Liu, Y. F. (2001) Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J. Biol. Chem. 276, 24713-24718.
71. Sun, Z., Xie, J. P., & Reiner, A. (2001) The differential vulnerability of striatal projection neurons in 3-nitropropionic acid-treated rats does not match that in Huntington's disease. Soc. Neuroci. Abstr. 31, 50.
72. Tabrizi, S. J., Workman, J., Hart, P. E., Mangiarini, L., Mahal, A., Bates, G., Cooper, J. M., & Schapira, A. H. (2000) Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann. Neurol. 47, 80-86.
73. 2A receptor signaling in striatal cells expressing mutant huntingtin. FASEB J.
74. Vis, J. C., Verbeek, M. M., De Waal, R. M., Ten Donkelaar, H. J., & Kremer, H. P. (1999) 3-Nitropropionic acid induces a spectrum of Huntington's disease-like neuropathology in rat striatum. Neuropathol. Appl. Neurobiol. 25, 513-521.
75. Vonsattel, J. P., Myers, R. H., Stevens, T. J., Ferrante, R. J., Bird, E. D., & Richardson, E. P., Jr. (1985) Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44, 559-577.
76. Wullner, U., Young, A. B., Penney, J. B., & Beal, M. F. (1994) 3-Nitropropionic acid toxicity in the striatum. J. Neurochem. 63, 1772-1781.
77. Yoshikawa, K., Maruyama, K., Aizawa, T., & Yamamoto, A. (1989) A new species of enkephalin precursor mRNA with a distinct 5′-untranslated region in haploid germ cells. FEBS Lett. 246, 193-196.
78. Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B. R., Goffredo, D., Conti, L., MacDonald, M. E., Friedlander, R. M., Silani, V., Hayden, M. R., Timmusk, T., Sipione, S., & Cattaneo, E. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293, 493-498.